Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
50
SUPN Quote, Financials, Valuation and Earnings
Last price:
$51.93
Seasonality move
:
6.18%
Day range:
$51.25 - $52.28
52-week range:
$29.16 - $57.65
Dividend yield:
0%
P/E ratio:
41.17x
P/S ratio:
4.28x
P/B ratio:
2.82x
Volume:
1.3M
Avg. volume:
760.3K
1-year change:
45.29%
Market cap:
$3B
Revenue:
$661.8M
EPS (TTM):
-$0.34
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SUPN
Supernus Pharmaceuticals, Inc.
|
$180.2M | $0.82 | 12.33% | 60.84% | $61.33 |
|
AMPH
Amphastar Pharmaceuticals, Inc.
|
$185.1M | $0.83 | 2.12% | 24.53% | $31.71 |
|
ASMB
Assembly Biosciences, Inc.
|
$7.5M | -$0.65 | 0.89% | -46.09% | $47.75 |
|
BBIO
BridgeBio Pharma, Inc.
|
$106.1M | -$0.78 | 2431.54% | -55.45% | $85.78 |
|
COO
The Cooper Cos., Inc.
|
$1.1B | $1.11 | 6.12% | 98.42% | $90.50 |
|
VKTX
Viking Therapeutics, Inc.
|
-- | -$0.67 | -- | -182.02% | $93.39 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SUPN
Supernus Pharmaceuticals, Inc.
|
$51.71 | $61.33 | $3B | 41.17x | $0.00 | 0% | 4.28x |
|
AMPH
Amphastar Pharmaceuticals, Inc.
|
$26.45 | $31.71 | $1.2B | 11.73x | $0.00 | 0% | 1.80x |
|
ASMB
Assembly Biosciences, Inc.
|
$32.61 | $47.75 | $515.8M | -- | $0.00 | 0% | 7.55x |
|
BBIO
BridgeBio Pharma, Inc.
|
$76.45 | $85.78 | $14.7B | -- | $0.00 | 0% | 41.16x |
|
COO
The Cooper Cos., Inc.
|
$82.88 | $90.50 | $16.2B | 44.23x | $0.01 | 0% | 4.05x |
|
VKTX
Viking Therapeutics, Inc.
|
$36.41 | $93.39 | $4.1B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SUPN
Supernus Pharmaceuticals, Inc.
|
3.87% | 0.900 | 1.55% | 1.37x |
|
AMPH
Amphastar Pharmaceuticals, Inc.
|
45.82% | 0.709 | 53.17% | 2.07x |
|
ASMB
Assembly Biosciences, Inc.
|
1.49% | 3.596 | 0.68% | 4.37x |
|
BBIO
BridgeBio Pharma, Inc.
|
350.59% | 0.711 | 27% | 3.52x |
|
COO
The Cooper Cos., Inc.
|
25.25% | 0.349 | 20.32% | 0.89x |
|
VKTX
Viking Therapeutics, Inc.
|
0.11% | 1.448 | 0.03% | 27.41x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SUPN
Supernus Pharmaceuticals, Inc.
|
$148.3M | -$61M | -1.78% | -1.84% | -31.77% | -$61.8M |
|
AMPH
Amphastar Pharmaceuticals, Inc.
|
$95M | $25.3M | 7.98% | 14.9% | 13.2% | $47.2M |
|
ASMB
Assembly Biosciences, Inc.
|
$10.8M | -$10.9M | -64.14% | -67.09% | -100.87% | -$15.2M |
|
BBIO
BridgeBio Pharma, Inc.
|
$113.4M | -$136.4M | -109.98% | -- | -112.97% | -$112.4M |
|
COO
The Cooper Cos., Inc.
|
$601M | $140.4M | 3.45% | 4.56% | 13.18% | $149.9M |
|
VKTX
Viking Therapeutics, Inc.
|
-$114K | -$98.6M | -28.59% | -28.62% | -- | -$94M |
Supernus Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns SUPN or AMPH?
Amphastar Pharmaceuticals, Inc. has a net margin of -23.49% compared to Supernus Pharmaceuticals, Inc.'s net margin of 9.04%. Supernus Pharmaceuticals, Inc.'s return on equity of -1.84% beat Amphastar Pharmaceuticals, Inc.'s return on equity of 14.9%.
Company Gross Margin Earnings Per Share Invested Capital SUPNSupernus Pharmaceuticals, Inc.77.21% -$0.80 $1.1B AMPHAmphastar Pharmaceuticals, Inc.49.53% $0.36 $1.4B -
What do Analysts Say About SUPN or AMPH?
Supernus Pharmaceuticals, Inc. has a consensus price target of $61.33, signalling upside risk potential of 18.61%. On the other hand Amphastar Pharmaceuticals, Inc. has an analysts' consensus of $31.71 which suggests that it could grow by 16.09%. Given that Supernus Pharmaceuticals, Inc. has higher upside potential than Amphastar Pharmaceuticals, Inc., analysts believe Supernus Pharmaceuticals, Inc. is more attractive than Amphastar Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SUPNSupernus Pharmaceuticals, Inc.4 1 0 AMPHAmphastar Pharmaceuticals, Inc.2 4 0 -
Is SUPN or AMPH More Risky?
Supernus Pharmaceuticals, Inc. has a beta of 0.715, which suggesting that the stock is 28.462% less volatile than S&P 500. In comparison Amphastar Pharmaceuticals, Inc. has a beta of 0.913, suggesting its less volatile than the S&P 500 by 8.747%.
-
Which is a Better Dividend Stock SUPN or AMPH?
Supernus Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amphastar Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Supernus Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Amphastar Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SUPN or AMPH?
Supernus Pharmaceuticals, Inc. quarterly revenues are $192.1M, which are larger than Amphastar Pharmaceuticals, Inc. quarterly revenues of $191.8M. Supernus Pharmaceuticals, Inc.'s net income of -$45.1M is lower than Amphastar Pharmaceuticals, Inc.'s net income of $17.4M. Notably, Supernus Pharmaceuticals, Inc.'s price-to-earnings ratio is 41.17x while Amphastar Pharmaceuticals, Inc.'s PE ratio is 11.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Supernus Pharmaceuticals, Inc. is 4.28x versus 1.80x for Amphastar Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SUPNSupernus Pharmaceuticals, Inc.4.28x 41.17x $192.1M -$45.1M AMPHAmphastar Pharmaceuticals, Inc.1.80x 11.73x $191.8M $17.4M
-
Which has Higher Returns SUPN or ASMB?
Assembly Biosciences, Inc. has a net margin of -23.49% compared to Supernus Pharmaceuticals, Inc.'s net margin of -85.24%. Supernus Pharmaceuticals, Inc.'s return on equity of -1.84% beat Assembly Biosciences, Inc.'s return on equity of -67.09%.
Company Gross Margin Earnings Per Share Invested Capital SUPNSupernus Pharmaceuticals, Inc.77.21% -$0.80 $1.1B ASMBAssembly Biosciences, Inc.99.7% -$0.72 $185.5M -
What do Analysts Say About SUPN or ASMB?
Supernus Pharmaceuticals, Inc. has a consensus price target of $61.33, signalling upside risk potential of 18.61%. On the other hand Assembly Biosciences, Inc. has an analysts' consensus of $47.75 which suggests that it could grow by 31.98%. Given that Assembly Biosciences, Inc. has higher upside potential than Supernus Pharmaceuticals, Inc., analysts believe Assembly Biosciences, Inc. is more attractive than Supernus Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SUPNSupernus Pharmaceuticals, Inc.4 1 0 ASMBAssembly Biosciences, Inc.4 0 0 -
Is SUPN or ASMB More Risky?
Supernus Pharmaceuticals, Inc. has a beta of 0.715, which suggesting that the stock is 28.462% less volatile than S&P 500. In comparison Assembly Biosciences, Inc. has a beta of 1.138, suggesting its more volatile than the S&P 500 by 13.805%.
-
Which is a Better Dividend Stock SUPN or ASMB?
Supernus Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Assembly Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Supernus Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Assembly Biosciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SUPN or ASMB?
Supernus Pharmaceuticals, Inc. quarterly revenues are $192.1M, which are larger than Assembly Biosciences, Inc. quarterly revenues of $10.8M. Supernus Pharmaceuticals, Inc.'s net income of -$45.1M is lower than Assembly Biosciences, Inc.'s net income of -$9.2M. Notably, Supernus Pharmaceuticals, Inc.'s price-to-earnings ratio is 41.17x while Assembly Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Supernus Pharmaceuticals, Inc. is 4.28x versus 7.55x for Assembly Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SUPNSupernus Pharmaceuticals, Inc.4.28x 41.17x $192.1M -$45.1M ASMBAssembly Biosciences, Inc.7.55x -- $10.8M -$9.2M
-
Which has Higher Returns SUPN or BBIO?
BridgeBio Pharma, Inc. has a net margin of -23.49% compared to Supernus Pharmaceuticals, Inc.'s net margin of -153.22%. Supernus Pharmaceuticals, Inc.'s return on equity of -1.84% beat BridgeBio Pharma, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SUPNSupernus Pharmaceuticals, Inc.77.21% -$0.80 $1.1B BBIOBridgeBio Pharma, Inc.93.98% -$0.95 $781.7M -
What do Analysts Say About SUPN or BBIO?
Supernus Pharmaceuticals, Inc. has a consensus price target of $61.33, signalling upside risk potential of 18.61%. On the other hand BridgeBio Pharma, Inc. has an analysts' consensus of $85.78 which suggests that it could grow by 11.27%. Given that Supernus Pharmaceuticals, Inc. has higher upside potential than BridgeBio Pharma, Inc., analysts believe Supernus Pharmaceuticals, Inc. is more attractive than BridgeBio Pharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SUPNSupernus Pharmaceuticals, Inc.4 1 0 BBIOBridgeBio Pharma, Inc.15 1 0 -
Is SUPN or BBIO More Risky?
Supernus Pharmaceuticals, Inc. has a beta of 0.715, which suggesting that the stock is 28.462% less volatile than S&P 500. In comparison BridgeBio Pharma, Inc. has a beta of 1.256, suggesting its more volatile than the S&P 500 by 25.58%.
-
Which is a Better Dividend Stock SUPN or BBIO?
Supernus Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BridgeBio Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Supernus Pharmaceuticals, Inc. pays -- of its earnings as a dividend. BridgeBio Pharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SUPN or BBIO?
Supernus Pharmaceuticals, Inc. quarterly revenues are $192.1M, which are larger than BridgeBio Pharma, Inc. quarterly revenues of $120.7M. Supernus Pharmaceuticals, Inc.'s net income of -$45.1M is higher than BridgeBio Pharma, Inc.'s net income of -$184.9M. Notably, Supernus Pharmaceuticals, Inc.'s price-to-earnings ratio is 41.17x while BridgeBio Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Supernus Pharmaceuticals, Inc. is 4.28x versus 41.16x for BridgeBio Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SUPNSupernus Pharmaceuticals, Inc.4.28x 41.17x $192.1M -$45.1M BBIOBridgeBio Pharma, Inc.41.16x -- $120.7M -$184.9M
-
Which has Higher Returns SUPN or COO?
The Cooper Cos., Inc. has a net margin of -23.49% compared to Supernus Pharmaceuticals, Inc.'s net margin of 7.94%. Supernus Pharmaceuticals, Inc.'s return on equity of -1.84% beat The Cooper Cos., Inc.'s return on equity of 4.56%.
Company Gross Margin Earnings Per Share Invested Capital SUPNSupernus Pharmaceuticals, Inc.77.21% -$0.80 $1.1B COOThe Cooper Cos., Inc.56.42% $0.43 $11B -
What do Analysts Say About SUPN or COO?
Supernus Pharmaceuticals, Inc. has a consensus price target of $61.33, signalling upside risk potential of 18.61%. On the other hand The Cooper Cos., Inc. has an analysts' consensus of $90.50 which suggests that it could grow by 9.19%. Given that Supernus Pharmaceuticals, Inc. has higher upside potential than The Cooper Cos., Inc., analysts believe Supernus Pharmaceuticals, Inc. is more attractive than The Cooper Cos., Inc..
Company Buy Ratings Hold Ratings Sell Ratings SUPNSupernus Pharmaceuticals, Inc.4 1 0 COOThe Cooper Cos., Inc.6 7 1 -
Is SUPN or COO More Risky?
Supernus Pharmaceuticals, Inc. has a beta of 0.715, which suggesting that the stock is 28.462% less volatile than S&P 500. In comparison The Cooper Cos., Inc. has a beta of 1.048, suggesting its more volatile than the S&P 500 by 4.779%.
-
Which is a Better Dividend Stock SUPN or COO?
Supernus Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Cooper Cos., Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.01 per share. Supernus Pharmaceuticals, Inc. pays -- of its earnings as a dividend. The Cooper Cos., Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SUPN or COO?
Supernus Pharmaceuticals, Inc. quarterly revenues are $192.1M, which are smaller than The Cooper Cos., Inc. quarterly revenues of $1.1B. Supernus Pharmaceuticals, Inc.'s net income of -$45.1M is lower than The Cooper Cos., Inc.'s net income of $84.6M. Notably, Supernus Pharmaceuticals, Inc.'s price-to-earnings ratio is 41.17x while The Cooper Cos., Inc.'s PE ratio is 44.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Supernus Pharmaceuticals, Inc. is 4.28x versus 4.05x for The Cooper Cos., Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SUPNSupernus Pharmaceuticals, Inc.4.28x 41.17x $192.1M -$45.1M COOThe Cooper Cos., Inc.4.05x 44.23x $1.1B $84.6M
-
Which has Higher Returns SUPN or VKTX?
Viking Therapeutics, Inc. has a net margin of -23.49% compared to Supernus Pharmaceuticals, Inc.'s net margin of --. Supernus Pharmaceuticals, Inc.'s return on equity of -1.84% beat Viking Therapeutics, Inc.'s return on equity of -28.62%.
Company Gross Margin Earnings Per Share Invested Capital SUPNSupernus Pharmaceuticals, Inc.77.21% -$0.80 $1.1B VKTXViking Therapeutics, Inc.-- -$0.81 $713.8M -
What do Analysts Say About SUPN or VKTX?
Supernus Pharmaceuticals, Inc. has a consensus price target of $61.33, signalling upside risk potential of 18.61%. On the other hand Viking Therapeutics, Inc. has an analysts' consensus of $93.39 which suggests that it could grow by 156.49%. Given that Viking Therapeutics, Inc. has higher upside potential than Supernus Pharmaceuticals, Inc., analysts believe Viking Therapeutics, Inc. is more attractive than Supernus Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SUPNSupernus Pharmaceuticals, Inc.4 1 0 VKTXViking Therapeutics, Inc.12 1 0 -
Is SUPN or VKTX More Risky?
Supernus Pharmaceuticals, Inc. has a beta of 0.715, which suggesting that the stock is 28.462% less volatile than S&P 500. In comparison Viking Therapeutics, Inc. has a beta of 0.649, suggesting its less volatile than the S&P 500 by 35.072%.
-
Which is a Better Dividend Stock SUPN or VKTX?
Supernus Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Supernus Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Viking Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SUPN or VKTX?
Supernus Pharmaceuticals, Inc. quarterly revenues are $192.1M, which are larger than Viking Therapeutics, Inc. quarterly revenues of --. Supernus Pharmaceuticals, Inc.'s net income of -$45.1M is higher than Viking Therapeutics, Inc.'s net income of -$90.8M. Notably, Supernus Pharmaceuticals, Inc.'s price-to-earnings ratio is 41.17x while Viking Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Supernus Pharmaceuticals, Inc. is 4.28x versus -- for Viking Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SUPNSupernus Pharmaceuticals, Inc.4.28x 41.17x $192.1M -$45.1M VKTXViking Therapeutics, Inc.-- -- -- -$90.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 24
Applied Optoelectronics, Inc. [AAOI] is up 5.1% over the past day.
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
